drugset / Trial / NCT06258031

PsilOCD: A Pharmacological-Challenge Feasibility Study

NCT06258031

Phase 1 Completed 19 enrolled Imperial College London
NaSingle-groupOpen-labelOther

Summary

The purpose of this study is to assess the impact of psilocybin on cognitive inflexibility and neural plasticity in a cohort of people with obsessive-compulsive disorder (OCD).

Timeline

Start
2022-10-28
Primary completion
2024-06-28
Completion
2024-07-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Psilocybin Other / unclassified 10 mg